Revolution Medicines, Inc. $RVMD Stock: Candriam S.C.A. Trims Position

Candriam S.C.A. lowered its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 19.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 445,693 shares of the company’s stock after selling 110,699 shares during the period. Candriam S.C.A. owned 0.21% of Revolution Medicines worth $91,817,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Burkett Financial Services LLC acquired a new position in Revolution Medicines in the third quarter valued at $27,000. Contravisory Investment Management Inc. purchased a new stake in shares of Revolution Medicines in the second quarter valued at about $32,000. Johnson Financial Group Inc. purchased a new stake in shares of Revolution Medicines in the second quarter valued at about $37,000. Silvant Capital Management LLC acquired a new stake in shares of Revolution Medicines during the second quarter worth about $41,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Revolution Medicines during the second quarter worth about $41,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RVMD has been the topic of a number of research reports. Bank of America lowered their price target on Revolution Medicines from $265.00 to $264.00 and set a “buy” rating on the stock in a report on Friday, October 9th. TD Cowen upped their price objective on Revolution Medicines from $250.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $275.00 price objective on shares of Revolution Medicines in a research note on Thursday, October 15th. Sanford C. Bernstein increased their price objective on Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a research report on Friday, August 21st. Finally, Evercore reaffirmed an “outperform” rating and set a $320.00 price objective on shares of Revolution Medicines in a research report on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $263.15.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

Insider Buying and Selling at Revolution Medicines

In other news, insider Stephen Kelsey sold 92,531 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $202.36, for a total transaction of $18,724,573.16. Following the transaction, the insider directly owned 291,876 shares in the company, valued at $59,064,027.36. The trade was a 24.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mark Goldsmith sold 80,000 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the transaction, the insider directly owned 267,330 shares of the company’s stock, valued at $55,925,436. This represents a 23.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 290,991 shares of company stock valued at $59,422,765. Insiders own 7.60% of the company’s stock.

Revolution Medicines Stock Performance

Shares of RVMD opened at $192.28 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 11.38 and a current ratio of 8.36. The stock has a market capitalization of $41.21 billion, a P/E ratio of -21.11 and a beta of 1.44. The company’s fifty day moving average is $196.88 and its two-hundred day moving average is $157.56. Revolution Medicines, Inc. has a 1 year low of $58.91 and a 1 year high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping the consensus estimate of ($2.35) by $0.45. The firm had revenue of $197.56 million during the quarter, compared to analyst estimates of $25.58 million. During the same quarter last year, the business posted ($1.61) EPS. On average, sell-side analysts predict that Revolution Medicines, Inc. will post -7.88 earnings per share for the current year.

About Revolution Medicines

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.